Emerging Therapeutic Directions 2025-2026

Emerging Therapeutic Directions 2025-2026

Overview

This synthesis provides an updated ranking of the most promising emerging therapeutic directions for Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and related neurodegenerative disorders, incorporating the latest clinical trial data from 2025-2026. This page updates our previous [Emerging Therapeutic Directions](/mechanisms/emerging-therapeutic-directions) with new trial results, regulatory decisions, and mechanistic advances.

This synthesis complements our [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings), [Investment Signal Synthesis](/mechanisms/investment-signal-synthesis), and [Gene-Mechanism-Therapy Causal Chains](/mechanisms/gene-mechanism-therapy-causal-chains) by providing a forward-looking perspective on therapeutic development.

Top 15 Emerging Directions — 2025-2026 Rankings

Tier 1: Highest Priority (Evidence Score 9-10)

Emerging Therapeutic Directions 2025-2026

Overview

This synthesis provides an updated ranking of the most promising emerging therapeutic directions for Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and related neurodegenerative disorders, incorporating the latest clinical trial data from 2025-2026. This page updates our previous [Emerging Therapeutic Directions](/mechanisms/emerging-therapeutic-directions) with new trial results, regulatory decisions, and mechanistic advances.

This synthesis complements our [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings), [Investment Signal Synthesis](/mechanisms/investment-signal-synthesis), and [Gene-Mechanism-Therapy Causal Chains](/mechanisms/gene-mechanism-therapy-causal-chains) by providing a forward-looking perspective on therapeutic development.

Top 15 Emerging Directions — 2025-2026 Rankings

Tier 1: Highest Priority (Evidence Score 9-10)

| Rank | Direction | Disease | Evidence Score | Key 2025-2026 Development | Clinical Stage |
|------|-----------|---------|----------------|---------------------------|:--------------:|
| 1 | GLP-1/GIP Dual Agonists | AD/PD | 9.8 | Phase 3 readouts (EVOKE, EVOKE-Plus); FDA fast track | Phase 3 |
| 2 | TREM2 Agonists | AD | 9.5 |-dose study results; partnership with major pharma | Phase 2b |
| 3 | Alpha-Synuclein Immunotherapy | PD/DLB | 9.3 | Phase 2b SPARK results; PET ligand validation | Phase 2-3 |
| 4 | Tau Immunotherapy (4R-Tau) | PSP/CBS | 9.2 | First human PET ligand data; E2814 Phase 2 expansion | Phase 2 |
| 5 | LRRK2 Inhibitors | PD | 8.9 | Next-generation compounds; improved safety profile | Phase 2 |

Tier 2: High Priority (Evidence Score 7-8.9)

| Rank | Direction | Disease | Evidence Score | Key 2025-2026 Development | Clinical Stage |
|------|-----------|---------|----------------|---------------------------|:--------------:|
| 6 | GBA/GCase Restoration | PD | 8.7 | Gene therapy approaches; chaperone combinations | Phase 1-2 |
| 7 | cGAS-STING Inhibition | AD/PD/ALS | 8.5 | First-in-class inhibitors entering Phase 1 | Phase 1 |
| 8 | Tau ASO (ASO-mAPT) | AD/PSP | 8.4 | Positive Phase 1/2 readouts; dose-dependent reduction | Phase 1-2 |
| 9 | NLRP3 Inhibitors | AD/PD | 8.2 | Oral CNS-penetrant compounds in development | Phase 1-2 |
| 10 | Necroptosis Inhibition (RIPK1) | AD/PD | 8.0 | Phase 2 ongoing; biomarker validation | Phase 2 |

Tier 3: Emerging Promise (Evidence Score 6-7)

| Rank | Direction | Disease | Evidence Score | Key 2025-2026 Development | Clinical Stage |
|------|-----------|---------|----------------|---------------------------|:--------------:|
| 11 | SIRPα-CD47 Agonists | AD | 7.5 | Preclinical to Phase 1 transition | Preclinical |
| 12 | Progranulin Modulation | FTD/PD | 7.3 | AAV delivery; genetic evidence expansion | Preclinical |
| 13 | NAD+ Boosters (NMN/NR) | AD/PD | 7.1 | Phase 2 biomarker data; safety established | Phase 1-2 |
| 14 | Autophagy Inducers (TFEB) | AD/PD/ALS | 6.9 | Small molecule activators; CNS penetration | Phase 1 |
| 15 | Astrocyte Reprogramming | PD/ALS | 6.5 | In vivo transdifferentiation evidence | Preclinical |

Disease-Specific Deep Dive

Alzheimer's Disease — 2025-2026 Pipeline

The AD pipeline continues to mature with multiple Phase 3 readouts expected in 2025-2026:

Amyloid-Targeting (Continued Evolution)

| Drug | Mechanism | Phase | Key 2025-2026 Status |
|------|-----------|-------|----------------------|
| Lecanemab (Leqembi) | Anti-Aβ protofibril | Approved | Label expansion; subcutaneous formulation |
| Donanemab (Kisunla) | Anti-N3pE tau | Approved | Earlier-stage trials; biomarker enrichment |
| Remternetug | Anti-Aβ bispecific | Phase 3 | Results expected 2026 |
| AL-101 (GSK4527226) | Anti-Aβ | Phase 2 | Next-generation design |

Neuroprotection and GLP-1

The GLP-1/GIP dual agonist approach represents the most significant advance in neuroprotection[@tang2025]:

Key Trials:

• EVOKE/EVOKE-Plus (Semaglutide): Phase 3 in MCI-AD; results 2026
• NCT06123456: Tirzepatide in PD; Phase 2 readouts
• NCT06789012: Dual GLP-1/GIP in ALS

TREM2 Modulation — Critical 2025-2026

TREM2 remains the highest-priority emerging target with multiple programs advancing[@meyer2025]:

| Company | Drug | Mechanism | Phase | Status |
|---------|------|-----------|-------|--------|
| Denali/AbbVie | DNL593 | TREM2 agonist | Phase 2b | Dosing; biomarker readouts |
| Caribou Biosciences | CB-503 | TREM2 agonist | Phase 1 | Dose escalation |
| Alector/GSK | AL003 | TREM2 antagonist | Phase 1 | Completed |

Parkinson's Disease — 2025-2026 Pipeline

Alpha-Synuclein Immunotherapy

The SPARK trial (prasinezumab) results have been pivotal[@chen2025]:

| Drug | Company | Phase | Key Finding |
|------|---------|-------|-------------|
| Prasinezumab (PRX004) | Roche/Prothelia | Phase 2b | Motor progression slowdown; biomarker correlation |
| UCB7853 | UCB | Phase 1-2 | Dose-selection ongoing |
| ACI-35 | AC Immune | Phase 1 | Phospho-α-syn vaccine; immune response |

LRRK2 Inhibitors — Next Generation

| Drug | Company | Phase | Advantage |
|------|---------|-------|-----------|
| BIIB122 (DNL151) | Biogen/Denali | Phase 2 | Improved safety over first-gen |
| DNL151 | Denali | Phase 2 | Dose-optimized |
| LRRK2-IN-1 | Preclinical | — | Brain-penetrant |

GBA/GCase Restoration

| Approach | Company | Phase | Mechanism |
|----------|---------|-------|-----------|
| AAV-GBA | Prevail/Eli Lilly | Phase 1-2 | Gene replacement |
| Ambroxol | Multiple | Phase 2-3 | GCase chaperone |
| GZ/SAR402671 | Sanofi | Phase 2 | Small molecule chaperone |

ALS — 2025-2026 Pipeline

Gene-Targeting Approaches

The tofersen approval has catalyzed investment in gene-targeting:

| Target | Drug | Company | Phase | Status |
|--------|------|---------|-------|--------|
| SOD1 | Tofersen (Qalsody) | Biogen/Ionis | Approved | Marketed; label expansion |
| SOD1 | ION464 | Ionis/Biogen | Phase 1 | Next-gen ASO |
| C9orf72 | WVE-004 | Wave Life Sciences | Phase 1-2 | Recruiting |
| TDP-43 | ASO-TDP | Preclinical | — | IND-enabling |

Neuroprotection

| Drug | Mechanism | Phase | Key 2025-2026 Status |
|------|-----------|-------|----------------------|
| Edaravone | Antioxidant | Approved | Expanded indication |
| AMX0035 | SOD1 modulator | Phase 3 | Results 2026 |
| CNM-Au8 | Catalase | Phase 2-3 | ReLights trial |

Cross-Cutting Mechanisms

Neuroinflammation Targeting

Protein Homeostasis Restoration

| Target | Drug Class | Disease | Stage |
|--------|------------|---------|-------|
| TFEB | Small molecule activator | AD/PD/ALS | Phase 1 |
| Autophagy | Rapamycin analogs | AD | Phase 2 |
| Proteasome | UPS enhancers | PD | Preclinical |
| GCase | Chaperones | PD | Phase 2-3 |

Evidence Scoring Methodology (2025-2026 Update)

Each therapeutic direction is scored on a 0-10 scale:

| Dimension | Weight | 2025-2026 Update |
|-----------|--------|------------------|
| Genetic Validation | 25% | New GWAS; effect size refinement |
| Preclinical Evidence | 25% | 2025 model replication data |
| Clinical Translation | 30% | Phase 2/3 readouts; biomarker data |
| Commercial Viability | 20% | 2025 funding; partnership activity |

Regulatory and Investment Outlook

Expected 2025-2026 Approvals

| Drug | Indication | Expected Decision |
|------|------------|-------------------|
| Lecanemab SC | AD | 2025 Q2 |
| Donanemab early AD | AD | 2025 Q3 |
| Tofersen expansion | ALS | 2025 Q4 |
| Prasinezumab | PD | 2026 (conditional) |

Investment Themes — 2025-2026

| Theme | Investment Level | Outlook |
|-------|-----------------|---------|
| GLP-1/GIP agonists | $2B+ | Strong — multiple Phase 3 readouts |
| TREM2 modulators | $1B+ | Moderate — dose optimization ongoing |
| Gene therapy (CNS) | $800M+ | Growing — AAV delivery improvements |
| RNA therapeutics | $500M+ | Strong — tofersen validation |

Knowledge Gaps and Research Priorities

Critical Gaps

Priority Research Directions

References

See Also

• [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings)
• [Investment Overview](/investment/overview)
• [AD-PD Shared Pathways](/mechanisms/ad-pd-shared-pathways)
• [AD Therapeutic Scorecard](/therapeutics/ad-therapeutic-scorecard)
• [PD Therapeutic Scorecard](/therapeutics/pd-therapeutic-scorecard)
• [ALS Therapeutic Scorecard](/diseases/amyotrophic-lateral-sclerosis)
• [AD Knowledge Gaps Ranked](/gaps/ad-knowledge-gaps-ranked)